287 related articles for article (PubMed ID: 25910030)
1. Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma.
Hwang S; Kim HE; Min M; Raghunathan R; Panova IP; Munshi R; Ryu B
J Invest Dermatol; 2015 Sep; 135(9):2283-2291. PubMed ID: 25910030
[TBL] [Abstract][Full Text] [Related]
2. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma.
Kongkham PN; Northcott PA; Ra YS; Nakahara Y; Mainprize TG; Croul SE; Smith CA; Taylor MD; Rutka JT
Cancer Res; 2008 Dec; 68(23):9945-53. PubMed ID: 19047176
[TBL] [Abstract][Full Text] [Related]
3. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
4. Serine peptidase inhibitor Kunitz type 2 (SPINT2) in cancer development and progression.
Roversi FM; Olalla Saad ST; Machado-Neto JA
Biomed Pharmacother; 2018 May; 101():278-286. PubMed ID: 29499401
[TBL] [Abstract][Full Text] [Related]
5. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells.
Parr C; Jiang WG
Int J Oncol; 2001 Oct; 19(4):857-63. PubMed ID: 11562767
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation and silencing of the SPINT2 gene in high-grade gliomas.
Fukushima T; Kawaguchi M; Yamamoto K; Yamashita F; Izumi A; Kaieda T; Takezaki Y; Itoh H; Takeshima H; Kataoka H
Cancer Sci; 2018 Sep; 109(9):2970-2979. PubMed ID: 29987920
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation and tumor suppressor activity of HAI-2/SPINT2 in gastric cancer.
Dong W; Chen X; Xie J; Sun P; Wu Y
Int J Cancer; 2010 Oct; 127(7):1526-34. PubMed ID: 20063316
[TBL] [Abstract][Full Text] [Related]
8. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetic analysis of the hepatocyte growth factor/MET signaling pathway in pediatric medulloblastoma.
Onvani S; Terakawa Y; Smith C; Northcott P; Taylor M; Rutka J
Genes Chromosomes Cancer; 2012 Jul; 51(7):675-88. PubMed ID: 22447520
[TBL] [Abstract][Full Text] [Related]
10. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype.
Otsuka T; Takayama H; Sharp R; Celli G; LaRochelle WJ; Bottaro DP; Ellmore N; Vieira W; Owens JW; Anver M; Merlino G
Cancer Res; 1998 Nov; 58(22):5157-67. PubMed ID: 9823327
[TBL] [Abstract][Full Text] [Related]
11. The Role of MET in Melanoma and Melanocytic Lesions.
Zhou Y; Song KY; Giubellino A
Am J Pathol; 2019 Nov; 189(11):2138-2148. PubMed ID: 31476283
[TBL] [Abstract][Full Text] [Related]
12. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells.
Halaban R; Rubin JS; Funasaka Y; Cobb M; Boulton T; Faletto D; Rosen E; Chan A; Yoko K; White W
Oncogene; 1992 Nov; 7(11):2195-206. PubMed ID: 1331934
[TBL] [Abstract][Full Text] [Related]
13. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.
Liu F; Cox CD; Chowdhury R; Dovek L; Nguyen H; Li T; Li S; Ozer B; Chou A; Nguyen N; Wei B; Antonios J; Soto H; Kornblum H; Liau L; Prins R; Nghiemphu PL; Yong W; Cloughesy T; Lai A
J Neurooncol; 2019 May; 142(3):423-434. PubMed ID: 30838489
[TBL] [Abstract][Full Text] [Related]
14. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer.
Kitajima Y; Ide T; Ohtsuka T; Miyazaki K
Cancer Sci; 2008 Jul; 99(7):1341-7. PubMed ID: 18422749
[TBL] [Abstract][Full Text] [Related]
15. Ezrin mediates both HGF/Met autocrine and non-autocrine signaling-induced metastasis in melanoma.
Huang L; Qin Y; Zuo Q; Bhatnagar K; Xiong J; Merlino G; Yu Y
Int J Cancer; 2018 Apr; 142(8):1652-1663. PubMed ID: 29210059
[TBL] [Abstract][Full Text] [Related]
16. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
[TBL] [Abstract][Full Text] [Related]
17. The hepatocyte growth factor regulatory factors in human breast cancer.
Parr C; Watkins G; Mansel RE; Jiang WG
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
[TBL] [Abstract][Full Text] [Related]
18. Pericellular activation of hepatocyte growth factor/scatter factor (HGF/SF) in colorectal carcinomas: roles of HGF activator (HGFA) and HGFA inhibitor type 1 (HAI-1).
Kataoka H; Itoh H; Hamasuna R; Meng JY; Koono M
Hum Cell; 2001 Mar; 14(1):83-93. PubMed ID: 11436357
[TBL] [Abstract][Full Text] [Related]
19. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
[TBL] [Abstract][Full Text] [Related]
20. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility.
Fang JD; Lee SL
Biochim Biophys Acta; 2014 Jul; 1843(7):1285-94. PubMed ID: 24685580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
